Episode
Could taking aspirin halve the risk of bowel cancer?
- Podcast
- Behind the Genes
- Published
- Jun 24, 2026
- Duration seconds
- 2180
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/behind-the-genes-3509739/episodes/could-taking-aspirin-halve-the-risk-of-bowel-cancer/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/behind-the-genes-3509739/could-taking-aspirin-halve-the-risk-of-bowel-cancer.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
A daily low dose of aspirin could significantly reduce the risk of bowel cancer in people with Lynch syndrome, an inherited condition that increases the likelihood of developing certain cancers. In this episode, we explore the findings from the landmark CaPP3 trial, hear from a participant living with Lynch syndrome, and discuss how genomics could help shift healthcare from treatment to prevention. Our host, Sharon Jones is joined by: Dr Katie Snape, Principal Clinician for Population Health at Genomics England Professor Sir John Burn, Professor of Clinical Genetics at Newcastle University Drew Hyde, participant in the Cancer Prevention Programme (CaPP3) Links: Listen to: How can genomics help us understand cancer? "I think knowing is always a good thing. And obviously, I wish I'd known earlier, and then, I could have taken more measures earlier on. So I think knowledge is definitely a good thing. And it would be great if more people could be tested or could find out if they were carriers at an early age, I think." You can download the transcript or read it below. [00:00:00] Sharon: Welcome to Behind the Genes. In today's episode, we'll explore the research which shows how a low dose of aspirin can halve the risk of bowel cancer in people with Lynch syndrome. We'll hear about the real-life impact of living with the condition, and look at how genomics can help shape a more preventative approach to care in the future. [00:00:20] I'm Sharon Jones, and to help us unpack all of that, I'm joined by our guests, Dr. Katie Snape, principal clinician for population health at Genomics England; Sir John Burn, professor of clinical genetics at Newcastle University; and Drew Hyde, a participant in the Cancer Prevention Programme, which is also known as the CaPP3 trial. [00:00:42] So…